RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aptose Biosciences - Stock

Aptose Biosciences Stocks 2024

Aptose Biosciences Stocks

6.76 M

Aptose Biosciences Dividend yield

Ticker

APS.TO

ISIN

CA03835T2002

WKN

A12C5N

In 2024, Aptose Biosciences had 6.76 M outstanding stocks, a 0% change from the 6.76 M stocks in the previous year.

The Aptose Biosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e6.76
2029e6.76
2028e6.76
2027e6.76
2026e6.76
2025e6.76
2024e6.76
20236.76
20226.15
20215.94
20205.46
20193.34
20182.23
20171.49
20160.85
20150.79
20140.35
20130.23
20120.11
20110.07
20100.05
20090.05
20080.04
20070.04
20060.03
20050.03
20040.03

Aptose Biosciences Aktienanalyse

What does Aptose Biosciences do?

The company Aptose Biosciences was founded in 1986 and is based in Toronto, Canada. It specializes in the discovery and development of drugs for the treatment of cancer and other serious diseases. History: Aptose Biosciences was originally known as Lorus Therapeutics, specializing in the development of antibodies and peptides. However, in 2007, the company changed its name to Aptose Biosciences and focused on cancer drugs. In 2011, Aptose obtained the license for CG'806, a promising cancer therapy that was later introduced into clinical development in 2017. Business model: Aptose Biosciences' business model is based on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company works closely with leading scientists and researchers to identify and develop new and innovative therapies that have the potential to improve patients' lives. Aptose Biosciences also collaborates with pharmaceutical companies worldwide to advance the development and commercialization of its products. Divisions: Aptose Biosciences focuses on two main areas: the discovery and development of cancer therapies and the discovery of biomarkers that can be used in the diagnosis and treatment of cancer. The cancer therapy division of Aptose focuses on the development of drugs that can target the causes of cancer. The company utilizes innovative technologies to identify and develop new and promising drug candidates that have the potential to improve the lives of patients with various types of cancer. The biomarker division of Aptose focuses on the discovery of biomarkers that can be useful in the diagnosis and treatment of cancer. The company collaborates closely with other companies and research institutions to identify and validate new biomarkers that can contribute to the improvement of cancer diagnosis and treatment. Products: Aptose Biosciences currently offers several cancer drugs that are in different stages of clinical development. The most promising product of Aptose Biosciences is CG'806, which is currently in phase 1 clinical development. CG'806 is a first-in-class cancer drug that has the potential to combat multiple types of cancer. Other products of Aptose Biosciences include APTO-253, which is used for the treatment of AML (acute myeloid leukemia), and APTO-267, which is used for the treatment of CLL (chronic lymphocytic leukemia). Additionally, Aptose Biosciences is working on the development of other cancer therapies that are in various stages of development. Conclusion: Aptose Biosciences is a leading biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company has several promising cancer therapies in different stages of clinical development, as well as a promising biomarker division specializing in cancer diagnosis and treatment. With a strong focus on innovation and collaboration, Aptose Biosciences remains an important player in cancer research and therapy. Aptose Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Aptose Biosciences's Shares Outstanding

Aptose Biosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Aptose Biosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Aptose Biosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Aptose Biosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Aptose Biosciences Stock

How many stocks are there of Aptose Biosciences?

The current number of stocks of Aptose Biosciences is 6.76 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Aptose Biosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Aptose Biosciences evolved in recent years?

The number of shares of Aptose Biosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Aptose Biosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Aptose Biosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Aptose Biosciences pay?

Over the past 12 months, Aptose Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptose Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptose Biosciences?

The current dividend yield of Aptose Biosciences is .

When does Aptose Biosciences pay dividends?

Aptose Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptose Biosciences?

Aptose Biosciences paid dividends every year for the past 0 years.

What is the dividend of Aptose Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptose Biosciences located?

Aptose Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptose Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptose Biosciences from 6/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2024.

When did Aptose Biosciences pay the last dividend?

The last dividend was paid out on 6/5/2024.

What was the dividend of Aptose Biosciences in the year 2023?

In the year 2023, Aptose Biosciences distributed 0 USD as dividends.

In which currency does Aptose Biosciences pay out the dividend?

The dividends of Aptose Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aptose Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aptose Biosciences

Our stock analysis for Aptose Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptose Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.